Cited 0 time in
Clinical Manifestations and Outcomes of Varicella-zoster Virus Endotheliitis
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Cho, Yong Wun | - |
| dc.contributor.author | Lee, Dong Woo | - |
| dc.contributor.author | Kim, Gyu Nam | - |
| dc.contributor.author | Kim, Hyun-A | - |
| dc.contributor.author | Kim, Seong-Jae | - |
| dc.date.accessioned | 2024-12-03T00:00:52Z | - |
| dc.date.available | 2024-12-03T00:00:52Z | - |
| dc.date.issued | 2019-12 | - |
| dc.identifier.issn | 0378-6471 | - |
| dc.identifier.issn | 2092-9374 | - |
| dc.identifier.uri | https://scholarworks.gnu.ac.kr/handle/sw.gnu/73345 | - |
| dc.description.abstract | Purpose: We evaluated the clinical manifestations of varicella-zoster virus (VZV)-induced endotheliitis and treatment outcomes. Methods: We retrospectively reviewed the medical records of patients exhibiting clinical manifestations of endotheliitis diagnosed as VZV endotheliitis via polymerase chain reaction (PCR) of anterior chamber puncture fluid from January 2013 to December 2018. Their clinical characteristics, treatments, and outcomes were analyzed. Results: Seven eyes of seven patients were diagnosed as VZV-affected via PCR of the aqueous humor. Mean patient age was 70.4 +/- 10.4 years and the average follow-up time 24.7 +/- 3.8 months. All eyes exhibited mild anterior chamber inflammation (trace to 1+). Four eyes were disciform in shape and three exhibited diffuse endotheliitis. Six patients evidenced intraocular pressures >21 mmHg. All patients were treated with oral antiviral agents; they were cured and no recurrence was noted. The mean best-corrected visual acuity (logMAR) increased significantly from 0.73 +/- 0.19 to 0.09 +/- 0.07 and the mean ocular pressure decreased significantly from 26.1 +/- 7.3 to 13.2 +/- 2.1 mmHg. Conclusions: VZV endotheliitis may present as mild inflammation of the anterior chamber with a disciform eye or diffuse corneal edema. Diagnosis is aided by VZV-specific PCR of anterior chamber fluid; oral antiviral agents are useful. Be diagnosed with PCR of anterior chamber, and be treated with oral antiviral agents. | - |
| dc.format.extent | 7 | - |
| dc.language | 한국어 | - |
| dc.language.iso | KOR | - |
| dc.publisher | KOREAN OPHTHALMOLOGICAL SOC | - |
| dc.title | Clinical Manifestations and Outcomes of Varicella-zoster Virus Endotheliitis | - |
| dc.type | Article | - |
| dc.publisher.location | 대한민국 | - |
| dc.identifier.doi | 10.3341/jkos.2019.60.12.1162 | - |
| dc.identifier.scopusid | 2-s2.0-85076811078 | - |
| dc.identifier.wosid | 000503431200007 | - |
| dc.identifier.bibliographicCitation | JOURNAL OF THE KOREAN OPHTHALMOLOGICAL SOCIETY, v.60, no.12, pp 1162 - 1168 | - |
| dc.citation.title | JOURNAL OF THE KOREAN OPHTHALMOLOGICAL SOCIETY | - |
| dc.citation.volume | 60 | - |
| dc.citation.number | 12 | - |
| dc.citation.startPage | 1162 | - |
| dc.citation.endPage | 1168 | - |
| dc.type.docType | Article | - |
| dc.identifier.kciid | ART002530924 | - |
| dc.description.isOpenAccess | Y | - |
| dc.description.journalRegisteredClass | scopus | - |
| dc.description.journalRegisteredClass | esci | - |
| dc.description.journalRegisteredClass | kci | - |
| dc.relation.journalResearchArea | Ophthalmology | - |
| dc.relation.journalWebOfScienceCategory | Ophthalmology | - |
| dc.subject.keywordPlus | HERPES-ZOSTER | - |
| dc.subject.keywordPlus | CYTOMEGALOVIRUS | - |
| dc.subject.keywordPlus | OPHTHALMICUS | - |
| dc.subject.keywordAuthor | Acyclovir | - |
| dc.subject.keywordAuthor | Endotheliitis | - |
| dc.subject.keywordAuthor | Varicella-zoster virus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
Gyeongsang National University Central Library, 501, Jinju-daero, Jinju-si, Gyeongsangnam-do, 52828, Republic of Korea+82-55-772-0532
COPYRIGHT 2022 GYEONGSANG NATIONAL UNIVERSITY LIBRARY. ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.
